J&J to Provide EU 200 Million Doses of COVID-19 Vaccine Candidate

Johnson & Johnson (J&J) has reached an advance purchase deal with the European Commission to provide up to 200 million doses of its COVID-19 vaccine candidate.

The agreement also includes an option for J&J to supply an additional 200 million doses for a total of 400 million.

J&J is currently evaluating the vaccine candidate, Ad26.COV2.S, in a single-dose, phase 3 trial that aims to enroll 60,000 participants in eight countries. The company also plans to start a late-stage two-dose study by year’s end.